EVALUATION OF CARDIOVASCULAR RISK IN HYPERTENSIVE MEN WITH ANDROGEN DEFICIENCY
DOI:
https://doi.org/10.11603/1811-2471.2018.v0.i1.8475Keywords:
hypertension, testosterone, cholesterol.Abstract
Data from numerous studies show the correlation of low testosterone in men with certain CVD risk factors such as obesity, type 2 diabetes, metabolic syndrome. Statistical approaches include the calculation of cardiovascular risk for general population, and their use for risk assessment in men with testosterone deficiency is still not well-described in the literature.
The aim of the study – to determine the most valid approach for assessment of cardiovascular risk in hypertensive men with androgen deficiency using the comparative analysis of Framingham, SCORE and PROCAM scales.
Material and Methods. The study included 50 male patients with a diagnosis of stage II hypertension and 11 healthy subjects who were included into the control group. All participants were subjected to the general clinical examination, evaluation of lipid profile and total serum testosterone (TT), cardiovascular risk assessment using Framingham scale (FS), SCORE and PROCAM scales. Depending on the level of TT, the patients were divided into 2 groups: 1 group (n = 27) – with testosterone deficiency, 2 group (n = 23) with normal TT level.
Results. Analysis of cardiovascular risk of the study participants showed that 55.6 % of men in group 1 and 43.5 % of group 2 had high cardiovascular risk according to FS, while PROCAM risk of over 20 % had 66.7 % and 39.1 % of patients respectively. 51.8 % of men in group 1 and 39.1 % of group 2 were in high risk cohort due to SCORE scale. There was no significant difference between the risk by FS and by SCORE between groups 1 and 2, while the difference between these groups was statistically significant when PROCAM scale was used. Negative correlation was found between cardiovascular risk and TT level, with a statistically significant correlation between TT and PROCAM (p <0.05).
Conclusions. The use of the PROCAM scale is the most reasonable for categorizing of cardiovascular risk in cohort of hypertensive men associated with androgen deficiency.
References
Timmis, A., Townsend, N., Gale, C., Grobbee, R., Maniadakis, N., & Flather, M. (2017). European Society of Cardiology: Cardiovascular Disease Statistics 2017. European Heart Journal. doi:10.1093/eurheartj/ehx628
Annual report on the health status of the population, the sanitary and epidemiological situation and the results of the Ukrainian health care system in 2016 (2017). Ministry of Health of Ukraine, State Institution "Ukrainian Institute for Strategic Studies of the Ministry of Health of Ukraine", 2016 (1), 36-44 [in Ukrainian].
Oskui, P. M., French, W. J., Herring, M. J., Mayeda, G. S., Burstein, S., & Kloner, R. A. (2013). Testosterone and the Cardiovascular System: A Comprehensive Review of the Clinical Literature. Journal of the American Heart Association, 2(6), e000272-e000272. doi:10.1161/jaha.113.000272
Saad, F. (2009). The role of testosterone in type 2 diabetes and metabolic syndrome in men. Arquivos Brasileiros de Endocrinologia & Metabologia, 53(8), 901-907. doi:10.1590/s0004-27302009000800002
Dubey, R. (2002). Sex hormones and hypertension. Cardiovascular Research, 53(3), 688-708. doi:10.1016/s0008-6363(01)00527-2
Barton, M., Prossnitz, E. R., & Meyer, M. R. (2012). Testosterone and Secondary Hypertension: New Pieces to the Puzzle. Hypertension, 59(6), 1101-1103. doi:10.1161/hypertensionaha.112.195149
Fogari, R., Preti, P., Zoppi, A., Fogari, E., Rinaldi, A., Corradi, L., & Mugellini, A. (2005). Serum Testosterone Levels and Arterial Blood Pressure in the Elderly. Hypertension Research, 28(8), 625-630. doi:10.1291/hypres.28.625
Ponholzer, A., & Madersbacher, S. (2009). Re: Christina Wang, Eberhard Nieschlag, Ronald Swerdloff, et al. Investigation, Treatment, and Monitoring of Late-Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. Eur Urol 2009;55:121–30. European Urology, 55(5), e92. doi:10.1016/j.eururo.2008.11.053
D'Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008). General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study. Circulation, 117(6), 743-753. doi:10.1161/circulationaha.107.699579
Assmann, G. (2002). Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Munster (PROCAM) Study. Circulation, 105(3), 310-315. doi:10.1161/hc0302.102575
Conroy, R. (2003). Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal, 24(11), 987-1003. doi:10.1016/s0195-668x(03)00114-3
Malkin, C. J., Pugh, P. J., Morris, P. D., Asif, S., Jones, T. H., & Channer, K. S. (2010). Low serum testosterone and increased mortality in men with coronary heart disease. Heart, 96(22), 1821-1825. doi:10.1136/hrt.2010.195412
Ohlsson, C., Barrett-Connor, E., Bhasin, S., Orwoll, E., Labrie, F., Karlsson, M. K., … Tivesten, Å. (2011). High Serum Testosterone Is Associated With Reduced Risk of Cardiovascular Events in Elderly Men. Journal of the American College of Cardiology, 58(16), 1674-1681. doi:10.1016/j.jacc.2011.07.019
Yeap, B. B. (2014). In Older Men, Higher Plasma Testosterone or Dihydrotestosterone Is an Independent Predictor for Reduced Incidence of Stroke but Not Myocardial Infarction. The Journal of Clinical Endocrinology & Metabolism, 99(12), 4565-4573. doi:10.1210/jc.2014-2664
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008). Low Serum Testosterone and Mortality in Older Men. The Journal of Clinical Endocrinology & Metabolism, 93(1), 68-75. doi:10.1210/jc.2007-1792
Chock, B., Lin, T., Li, C., & Swislocki, A. (2012). Plasma testosterone is associated with Framingham risk score. The Aging Male, 15(3), 134-139. doi:10.3109/13685538.2011.654369
